SCHEMBL12786124

SCHEMBL12786124

Cc1cc(Cl)cc([S+]([O-])c2cc(Cl)cc(Cl)c2O)c1O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.45
TSHR P16473 3/20 0.45
HSD17B10 Q99714 3/20 0.45
CYP3A4 P08684 2/20 0.45
RECQL P46063 2/20 0.45
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
MAPT P10636 2/20 0.37
HPGD P15428 2/20 0.37
TTR P02766 2/20 0.37
KDM4E B2RXH2 1/20 0.37
SLC22A2 O15244 1/20 0.37
SLC22A1 O15245 1/20 0.37
NR1I2 O75469 1/20 0.37
SLC22A3 O75751 1/20 0.37
EGFR P00533 1/20 0.37
LMNA P02545 1/20 0.37
ESR1 P03372 1/20 0.37
ERBB2 P04626 1/20 0.37
LCK P06239 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bithionoloxide SCHEMBL69373 0.89 HSD17B10 (0.56) ALDH1A1TSHRHSD17B10CYP3A4RECQL
SCHEMBL30804415 0.78 ALDH1A1 (0.65) ALDH1A1TSHRHSD17B10CYP3A4RECQL
SCHEMBL1893469 0.78 ALDH1A1 (0.65) ALDH1A1TSHRHSD17B10CYP3A4RECQL
Bithionoloxide SCHEMBL11549920 0.73 TSHR (0.40) ALDH1A1TSHRHSD17B10CYP3A4RECQL
SCHEMBL3337579 0.72 TSHR (0.39) ALDH1A1TSHRHSD17B10CYP3A4RECQL
SCHEMBL29904878 0.72 TSHR (0.39) ALDH1A1TSHRHSD17B10CYP3A4RECQL
SCHEMBL1182540 0.71 CA1 (0.58) ALDH1A1TSHRHSD17B10CYP3A4RECQL
SCHEMBL5372785 0.70 HSD17B10 (0.40) ALDH1A1TSHRHSD17B10CYP3A4RECQL
SCHEMBL29904874 0.70 HSD17B10 (0.40) ALDH1A1TSHRHSD17B10CYP3A4RECQL
SCHEMBL14644985 0.67 HSD17B10 (0.77) ALDH1A1TSHRHSD17B10CYP3A4RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170281649-A1 COMPOUNDS AND THERAPEUTIC USES UNITY BIOTECHNOLOGY, INC. 2017-10-05 US disclosed
WO-2011041731-A2 METHOD OF INHIBITING BCL-2-RELATED SURVIVAL PROTEINS FRED HUTCHINSON CANCER RESEARCH CENTER (US) 2011-04-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170281649-A1 COMPOUNDS AND THERAPEUTIC USES TP53, NQO1, SHMT2 ALDH1A1 545/4885TSHR 3771/4885HSD17B10 2430/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.